The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis

Yükleniyor...
Küçük Resim

Tarih

2011

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Immunopharmacology and Immunotoxicology

Erişim Hakkı

info:eu-repo/semantics/openAccess

Özet

Inflammatory bowel diseases are characterized by disabilities in gastrointestinal system and defects in mucosal immune system. Statins are 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor and are used to treat hypercholesterolemia in patients with coronary artery and atherosclerotic diseases. Recent studies have demonstrated that statins have immunomodulatory role by effecting different pathways in immune system. In this study, we investigated the effect of atorvastatin and its mechanism on systemic immune response in treatment of trinitrobenzene sulfonic acid (TNBS)-induced colitis mice. We observed that atorvastatin significantly suppressed the severity of TNBS-induced colitis in BALB/c mice. This was manifested in reduced rectal bleeding, decrease in colon length, reduction of histological damage, and improved survival. Concurrently, we investigated the immunomodulatory role of atorvastatin on systemic immune system. We investigated the proinflammatory (IL-1α, IL-6, TNF-α), Th1 (IFN-γ, IL-2), Th2 (IL-4, IL-5, IL-10), and Th17 (IL-17, IL-23) cytokine levels in serum samples of colitis and atorvastatin-administered mice. We discovered that administration of atorvastatin significantly down-regulates systemic TNF-α level and Th17 cytokine levels. Furthermore, atorvastatin treatment switches Th1 type T-cell response toward/to Th2 (IL-4, IL-10) type response.

Açıklama

Anahtar Kelimeler

Inflammatory bowel diseases, Statin, Systemic immune response, Th1, Th2, Th17, Cytokines

Kaynak

Immunopharmacology and Immunotoxicology

WoS Q Değeri

Scopus Q Değeri

Cilt

33

Sayı

4

Künye

Aktunç, E. Kayhan, B. Araslı, M. Doğan Gün, B. Barut, F. (2011). The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis. Immunopharmacology and Immunotoxicology, 33(4), 667–675.